Syngene sees pipeline traction, bets on biologics for growth beyond FY27
Summary
Syngene anticipates growth beyond FY27, focusing on biologics despite recent profit declines due to client-specific challenges.
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.